A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Newly-diagnosed Philadelphia-negative All
  • Age: Between 22 - 65 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Newly-diagnosed and cytologically confirmed and documented Philadelphia-negative B-cell or T-cell ALL. 2) Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2. 3) No prior therapy for ALL such as chemotherapy and radiation therapy before signing the informed consent except for limited treatment (=7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine.

You may not be eligible for this study if the following are true:

  • 1) Patients with Philadelphia chromosome positive ALL, Burkitt’s leukemia, mixed lineage/mixed phenotype acute leukemia, and acute undifferentiated leukemia. 2) Patients with Down syndrome. 3) Participants known to be HIV-positive.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.